The Shulgin Legacy: From MDMA to Modern Medicine

From Alexander “Sasha” Shulgin’s groundbreaking synthesis of MDMA and hundreds of novel psychedelic compounds to Ann Shulgin’s pioneering work in psychedelic therapy, the Shulgins helped lay the foundation for today’s psychedelic renaissance. As MDMA approaches FDA approval and psychedelic medicine enters the mainstream, this panel explores how their methodologies, ethics, and community-centered approach remain vital guides for the field’s evolution.Through the lens of the historic Shulgin Farm’s transformation into a center for psychedelic education and community, panelists will examine:-Scientific Innovation: How the Shulgins’ systematic approach to drug development and testing—combining rigorous chemistry with careful documentation of subjective effects—provides a model for modern psychedelic research.-Therapeutic Wisdom: The enduring relevance of Ann Shulgin’s therapeutic frameworks and the importance of maintaining a balance between scientific advancement and human-centered care.-Legacy Preservation: The critical task of protecting and sharing the Shulgins’ extensive archives, methodologies, and philosophical approaches with a new generation of researchers and practitioners.-Community Building: Carrying forward the Shulgins’ tradition of fostering dialogue between scientists, therapists, and wisdom-keepers during a period of rapid industry growth and regulatory change.The session will particularly interest researchers, clinicians, and advocates seeking to understand how historical approaches can inform contemporary challenges in psychedelic science, therapy, and community building.